Antioxidant and anti-inflammatory effects of resveratrol in adults with bronchiectasis

Health Research Council of New Zealand0 个研究点目标入组 40 人开始时间: 2020年7月3日最近更新: 2020年7月13日

适应症

试验速览

暂无简介。

•Aged 18 years or over
•Able to provide written informed consent
•Able to provide spontaneous sputum sample at visit 2 (week 0)
•High-resolution CT (HRCT) chest scan confirming bronchiectasis within the last 5 years
•Clinically stable during baseline period, for 4 weeks before treatment commencement (defined as absence of clinical worsening beyond normal daily variation, with no need for increasing habitual medications or taking antibiotics or prednisone and stable spirometry)
•History of at least 1 pulmonary exacerbation requiring antibiotics in the past 12 months
•Patients with asthma and/or COPD will be included if the primary diagnosis is bronchiectasis

•Oral, intravenous or inhaled antibiotics within 4 weeks prior to commencing study
•Patients taking continuous macrolide therapy (for 3 months or longer) within 3 months of screening
•Patients taking continuous oral corticosteroids (for 6 weeks or longer) or immunosuppressive agents (e.g. azathioprine, methotrexate, cyclophosphamide)
•Bronchiectasis exacerbation / respiratory infection requiring oral or intravenous antibiotic treatment within 4 weeks prior to commencing study treatment
•Use of prescribed or dietary antioxidant supplement within 1 month of screening
•Body mass index <18.5 kg/m2
•Patients with a history of non-compliance with medications
•Patients with significant medical conditions other than bronchiectasis:
•Patients with cystic fibrosis
•Patients with primary ciliary dyskinesia
•Patients with hypogammaglobulinaemia or other primary or acquired immunodeficiency
•Patients with allergic bronchopulmonary aspergillosis
•Pregnant or lactating women
•Participation in a separate clinical or device trial within 4 weeks of screening
•Allergy to any components of Transmax
•Patients with evidence of active or suspected cancer

发起方